Paolo Bidoli

9.4k total citations · 2 hit papers
127 papers, 3.1k citations indexed

About

Paolo Bidoli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Paolo Bidoli has authored 127 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 20 papers in Epidemiology. Recurrent topics in Paolo Bidoli's work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Paolo Bidoli is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (36 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Paolo Bidoli collaborates with scholars based in Italy, United States and France. Paolo Bidoli's co-authors include Diego Cortinovis, Filippo de Marinis, Luis Paz‐Ares, Annamaria H. Zimmermann, Mircea Dediu, Nadia Chouaki, Michael Thomas, Martin Reck, Eckart Laack and William J. John and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Paolo Bidoli

126 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. profile →
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paolo Bidoli Italy	27	2.0k	1.9k	531	365	292	127	3.1k
Eun Kyung Cho South Korea	29	2.0k 1.0×	2.1k 1.1×	756 1.4×	386 1.1×	397 1.4×	134	3.6k
Ofer Merimsky Israel	30	1.2k 0.6×	1.3k 0.7×	482 0.9×	581 1.6×	259 0.9×	188	2.9k
Kathryn A. Gold United States	29	2.1k 1.1×	1.8k 1.0×	922 1.7×	338 0.9×	463 1.6×	99	3.5k
Thomas Brodowicz Austria	28	2.4k 1.2×	2.0k 1.1×	585 1.1×	417 1.1×	468 1.6×	126	3.4k
Kostas Syrigos Greece	30	1.6k 0.8×	1.1k 0.6×	1.0k 1.9×	352 1.0×	428 1.5×	114	3.3k
N. Colombo Italy	21	2.3k 1.2×	863 0.5×	466 0.9×	377 1.0×	207 0.7×	63	5.0k
Muhammad Wasif Saif United States	25	1.7k 0.9×	639 0.3×	562 1.1×	475 1.3×	222 0.8×	129	2.7k
Diego Cortinovis Italy	32	2.2k 1.1×	1.5k 0.8×	605 1.1×	344 0.9×	360 1.2×	181	3.4k
Giuseppina Catalano Italy	28	1.4k 0.7×	835 0.4×	268 0.5×	377 1.0×	242 0.8×	72	2.2k
Jeanny B. Aragon‐Ching United States	27	1.4k 0.7×	1.2k 0.6×	692 1.3×	600 1.6×	455 1.6×	141	2.9k

Countries citing papers authored by Paolo Bidoli

Since Specialization

Citations

This map shows the geographic impact of Paolo Bidoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Bidoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Bidoli more than expected).

Fields of papers citing papers by Paolo Bidoli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Bidoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Bidoli. The network helps show where Paolo Bidoli may publish in the future.

Co-authorship network of co-authors of Paolo Bidoli

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Bidoli. A scholar is included among the top collaborators of Paolo Bidoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Bidoli. Paolo Bidoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Byoung Chul Cho, Joo-Hang Kim, et al.. (2020). Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 147. 137–142. 40 indexed citations

Massironi, Sara, Lorenzo Pilla, Alessandra Elvevi, et al.. (2020). New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells. 9(3). 688–688. 65 indexed citations

Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468. 1 indexed citations

Luciani, Andrea, Luca Toschi, S. Fava, et al.. (2018). Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience. Annals of Oncology. 29. viii533–viii533. 6 indexed citations

Bossi, Paolo, Diego Cortinovis, Sonia Fatigoni, et al.. (2017). A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Annals of Oncology. 28(10). 2547–2551. 52 indexed citations

Palmero, Ramón, Paolo Bidoli, Igor Bondarenko, et al.. (2017). Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer. Annals of Oncology. 28. v487–v487. 1 indexed citations

Bidoli, Paolo, Rita Chiari, Annamaria Catino, et al.. (2016). Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Annals of Oncology. 27. vi425–vi425. 18 indexed citations

Crinò, Lucio, Paolo Bidoli, Angelo Delmonte, et al.. (2016). Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population. Annals of Oncology. 27. iv3–iv3. 1 indexed citations

Grossi, Francesco, Lucio Crinò, A. Misino, et al.. (2016). Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. Annals of Oncology. 27. vi369–vi369. 5 indexed citations

10.

Pagni, Fabio, Francesco Vacirca, Davide Leni, et al.. (2015). C-Arm Cone-Beam CT-Guided Transthoracic Lung Core Needle Biopsy as a Standard Diagnostic Tool. Medicine. 94(12). e698–e698. 7 indexed citations

11.

Bidoli, Paolo, Federico Cappuzzo, Adolfo Favaretto, et al.. (2015). Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology. Annals of Oncology. 26. vi74–vi74. 2 indexed citations

12.

Cortinovis, Diego, Stefania Canova, & Paolo Bidoli. (2015). What are the Options for Non-Small-Cell Lung Cancer Patients Post Second-Line Therapy?. Future Oncology. 11(17). 2379–2382. 1 indexed citations

13.

Cortinovis, Diego, Lital Hollander, Irene Floriani, et al.. (2015). Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM). Annals of Oncology. 26. vi75–vi75. 1 indexed citations

14.

Cappuzzo, Federico, Giovanna Finocchiaro, Francesco Grossi, et al.. (2014). Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(4). 665–672. 22 indexed citations

15.

Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2013). PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(23). 2895–2902. 438 indexed citations breakdown →

16.

Cascinu, Stefano, Rossana Berardi, Alberto F. Sobrero, et al.. (2013). Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease. 46(2). 182–186. 41 indexed citations

17.

Cortinovis, Diego, Francesca Andriani, Alessandra Fabbri, et al.. (2008). FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer. Current Cancer Drug Targets. 8(5). 342–348. 10 indexed citations

18.

Bidoli, Paolo, Nicoletta Zilembo, Diego Cortinovis, et al.. (2006). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Annals of Oncology. 18(3). 461–467. 28 indexed citations

19.

Bajetta, Emilio, Simonetta Chiara Stani, Nadia Zaffaroni, et al.. (2003). Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IVnon-small-cell lung cancer. Annals of Oncology. 14(2). 242–247. 15 indexed citations

20.

Bidoli, Paolo. (2003). Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. Lung Cancer. 43(2). 203–208. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact